These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2032 related items for PubMed ID: 25199059

  • 1. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P, MENSA Investigators.
    N Engl J Med; 2014 Sep 25; 371(13):1198-207. PubMed ID: 25199059
    [Abstract] [Full Text] [Related]

  • 2. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators.
    N Engl J Med; 2014 Sep 25; 371(13):1189-97. PubMed ID: 25199060
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T, Odajima H, Okamasa A, Kawase M, Komatsubara M, Mayer B, Yancey S, Ortega H.
    Allergol Int; 2017 Jul 25; 66(3):445-451. PubMed ID: 28110896
    [Abstract] [Full Text] [Related]

  • 4. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG.
    Clin Ther; 2016 Sep 25; 38(9):2058-2070.e1. PubMed ID: 27553751
    [Abstract] [Full Text] [Related]

  • 5. Anti-IL5 therapies for asthma.
    Farne HA, Wilson A, Powell C, Bax L, Milan SJ.
    Cochrane Database Syst Rev; 2017 Sep 21; 9(9):CD010834. PubMed ID: 28933516
    [Abstract] [Full Text] [Related]

  • 6. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
    Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P.
    Lancet; 2012 Aug 18; 380(9842):651-9. PubMed ID: 22901886
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May 18; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 8. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H.
    Allergy; 2016 Sep 18; 71(9):1335-44. PubMed ID: 27087007
    [Abstract] [Full Text] [Related]

  • 9. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos JP, Kwon N.
    Respir Med; 2019 Sep 18; 154():69-75. PubMed ID: 31220806
    [Abstract] [Full Text] [Related]

  • 10. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Lemiere C, Taillé C, Lee JK, Smith SG, Mallett S, Albers FC, Bradford ES, Yancey SW, Liu MC.
    Respir Res; 2021 Jun 22; 22(1):184. PubMed ID: 34158028
    [Abstract] [Full Text] [Related]

  • 11. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.
    Lancet Respir Med; 2016 Jul 22; 4(7):549-556. PubMed ID: 27177493
    [Abstract] [Full Text] [Related]

  • 12. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M.
    Clin Ther; 2019 Oct 22; 41(10):2041-2056.e5. PubMed ID: 31447130
    [Abstract] [Full Text] [Related]

  • 13. Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study.
    Nelsen LM, Cockle SM, Gunsoy NB, Jones P, Albers FC, Bradford ES, Mullerova H.
    J Asthma; 2020 Sep 22; 57(9):1006-1016. PubMed ID: 31251094
    [Abstract] [Full Text] [Related]

  • 14. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, Galkin D, Azmi J, Mouneimne D, Price RG, Liu MC.
    Allergy; 2019 Sep 22; 74(9):1716-1726. PubMed ID: 31049972
    [Abstract] [Full Text] [Related]

  • 15. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, Yancey SW, Smith SG, Bel EH.
    Respir Res; 2021 Jun 07; 22(1):171. PubMed ID: 34098955
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies.
    Kim MK, Park HS, Park CS, Min SJ, Albers FC, Yancey SW, Mayer B, Kwon N.
    Korean J Intern Med; 2021 Mar 07; 36(2):362-370. PubMed ID: 32450626
    [Abstract] [Full Text] [Related]

  • 17. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, Price RG, Galkin DV, Azmi J, Mouneimne D, Albers FC, Chapman KR.
    Respir Res; 2021 May 10; 22(1):144. PubMed ID: 33971856
    [Abstract] [Full Text] [Related]

  • 18. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
    van Toor JJ, van der Mark SC, Kappen JH, In 't Veen JCCM, Braunstahl GJ.
    J Asthma; 2021 May 10; 58(5):651-658. PubMed ID: 31999203
    [Abstract] [Full Text] [Related]

  • 19. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG, ANDHI study investigators.
    Lancet Respir Med; 2021 Mar 10; 9(3):260-274. PubMed ID: 33357499
    [Abstract] [Full Text] [Related]

  • 20. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma.
    Kurosawa M, Sutoh E.
    J Investig Allergol Clin Immunol; 2019 Mar 10; 29(1):40-45. PubMed ID: 29957591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 102.